Evidence level: B
导言
心气虚是中医辨证中最常用于评估心功能状态的核心证候。传统临床判断依赖医家指下经验,分级(轻/中/重)一致性受操作者影响显著。王唯工等提出的脉搏谐波理论(Harmonic Ratio Index, HRI)将桡动脉压力波分解为 10 个谐波分量(记为 C0–C10),其中 C0 为直流分量反映总脉能,C1–C10 分别代表不同脏腑器官的谐波贡献度。该理论的核心假说为:C1 关联肝、C2 关联心、C3 关联脾、C4 关联肺、C5–C10 关联肾与三焦。在此框架下,C2 与 C3 的比值(或绝对强度)随证候严重程度是否呈现可量化的剂量-反应曲线,是把中医辨证从”经验判断”推进到”频率指纹”的关键证据链。
核心证据回顾
1. 谐波分析在中医辨证中的整体应用(系统综述)
Hsiao 等 2024 年发表于 J Tradit Complement Med 的系统综述(PMID 38481553,1990–2021 年 50 篇研究报告)确认:肝功能障碍与 C1 变化相关;糖尿病患者出现 C3(脾相关)减弱;癌症患者在 C1、C2 呈现肝肾阴虚的谐波特征;心血管疾病患者则表现为与肝经相关的第一谐波升高。综述明确指出”谐波强度模式在不同生理与病理状态下具有可区分特征”,但同时强调”样本量小、研究异质性大”是当前主要局限——这恰好是本课题关心的”剂量-反应关系”在严谨统计框架下尚未被独立验证的原因。
2. 心血管疾病群体的谐波特征
Chang 等 2016 年发表于 Microvasc Res 的研究(PMID 27067750)对代谢综合征(MetS)患者进行 PPG 谐波分析,结果显示 MS 组 C1、C2 显著减小,而 C4–C9 显著或趋势性增大;C_n 标准差与变异系数在 MS 组最大。该研究提示:C1/C2 减弱与心血管功能失调存在关联,但研究设计为横断面、单一中心(n=65),无法建立严重程度分级与谐波比率的连续曲线。
3. 五脏谐波—ML 分类的可行性
Wu 等 2022 年发表于 Sci Rep(PMID 36509825)使用 40 项谐波指标(振幅比例 + 变异系数 + 相位 + 标准差)对肌少症进行 LDA 分类,AUC=0.77(评分系统 AUC=0.83)。这证明:多谐波特征联合可在中等样本下达到可接受的判别力——本课题的关键不是单谐波是否有用,而是如何用 C2/C3 这一对特定谐波比量化心气虚分级。
4. 谐波-证候的双向标定基础
Chen 等 2020 年发表于 Evid Based Complement Alternat Med(PMID 33082826)证实”放松活动增加高次谐波、应激活动增加低次谐波”,提示生理状态变化会通过 C1–C10 比例关系反映;Wu 等 2016 年 PLoS One(PMID 27304979)的 Synchrosqueezing Transform 方法学为心气虚分级的频域精细分析提供了工具基础;Lin 等 2021 年 Sci Rep(PMID 33903610)将 40 项谐波指标用于阿尔茨海默病分类,AUC≈0.85,进一步支持”多谐波组合 + ML”范式在不同脏腑系统间的可迁移性。
当前研究的关键缺口
将上述证据综合,可识别出 #88 课题(心气虚轻/中/重三级剂量-反应)的三个具体证据缺口:
- 缺少”单证候-单谐波对”的剂量-反应曲线:既有研究多为二分类(病/对照)或三分类(健康/前驱/病),未在中医辨证内部对单一证候做”轻-中-重”分级的连续建模。
- C2/C3 比的混杂校正缺失:心气虚常合并气阴两虚、心脾两虚,C2 与 C3 同时受多脏腑功能影响;既有研究未控制合并证候,剂量-反应关系被合并效应污染。
- 方法学异质性使 Meta-分析不可行:综述(PMID 38481553)已声明”测量方法与人群异质性”是主要缺陷;不同采集设备(PPG / 压力传感)、不同按压力度、不同样本数都限制了谐波比值跨研究的可比性。
假设与剂量-反应预期
基于谐波理论与现有证据,本课题的工作假设为:
在控制年龄、性别、BMI、合并证候、采集压力后,C2(心相关)/C3(脾相关)比值随中医心气虚严重程度(轻→中→重)单调递减,斜率反映心气”功能储备”消耗程度。
该假设的合理性来自:心气虚加重时,心脏泵功能下降 → 桡动脉波 C2 分量绝对强度下降;脾虚共病则同时拉低 C3。若 C2/C3 同步下降,则比值变化可作为”心气虚主导” vs “心脾两虚”的鉴别指标;若C2 下降而 C3 不变(即 C2/C3 下降),则比值是心气虚特异的剂量-反应标志。
证据边界与局限
- 现有 PMID 证据均为横断面/回顾性研究,无法支持因果推断;
- 心气虚诊断标准在不同辨证规范(1993 / 2017 / 2023)中存在差异,会导致同群体分级标签漂移——本课题需要在实验设计中明确锚定哪一版标准;
- 谐波-证候映射目前依赖”经脉-脏腑-谐波”假说(E2 间接证据链),并非已证因果;
- C2/C3 比值对采集压力敏感,必须配 PCHR 压力补偿(参见本池 #32 课题)才能保证跨研究可比性。
拟验证的下一步
本课题推荐执行”三阶段、单中心前瞻性 + 多中心外部验证”研究(详见配套实验设计 P3-EXP-023):
- 阶段一:N=60 健康对照 vs N=180 心气虚(轻/中/重各 60)单中心,采集 PPG + 桡动脉压力波;
- 阶段二:N=300 大样本验证剂量-反应曲线,纳入混杂校正(年龄/性别/BMI/合并证候);
- 阶段三:N=120 多中心外部验证 + PCHR 压力补偿的跨设备迁移性检验。
预期产物:C2/C3 比值的轻/中/重三段参考区间 + 调整混杂后的趋势 p 值 + 跨设备 ICC。
证据等级说明
- A 级:RCT 或多中心前瞻性队列直接证明(当前缺失)
- B 级:多研究间接证据链 + 系统综述支持(本课题当前位置)
- C 级:单中心横断面或回顾性研究(多数现有 PMID 落在此层)
本课题在取得阶段二、阶段三证据前,应保持 B 级(间接证据链);阶段二完成后可升至 A-(单中心前瞻);阶段三完成后可挑战 A 级。
相关阅读
- 本池 #87 脉搏谐波频谱与时域特征的证候区分能力循证映射
- 本池 #32 PCHR 算法的深度学习自适应压力补偿(实验编号 P3-EXP-016)
- 本池 #29 压力归一化算法与跨操作者 HRI 可比性验证(PMID 27861248, 27314975, 31730401, 33901427, 1402.6649)
- 本池 #23 二十八脉 HRI 操作者间信度的操作员培训标准化
免责声明
本文为研究综述与课题框架,不构成医疗建议。心气虚辨证与治疗须由具备执业资格的中医师进行;HRI 谐波分析为研究工具,临床诊断需结合症状、舌脉、实验室检查等综合判断。
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Dose-response relationship between HRI harmonic C2/C3 and severity grading of heart qi deficiency
Evidence level: B
Introduction
Heart Qi Deficiency is a core syndrome pattern in Traditional Chinese Medicine (TCM) diagnosis most frequently utilized to assess cardiac function status. Traditional clinical judgment relies heavily on practitioner experience under the pulse, and consistency in grading (mild/moderate/severe) varies significantly among operators. The Harmonic Ratio Index (HRI) theory proposed by Wang Weigong et al. decomposes the radial artery pressure wave into 10 harmonic components (denoted as C0–C10), where C0 represents the DC component reflecting total pulse energy, and C1–C10 represent harmonic contributions from different zang-fu organs. The core hypothesis of this theory is: C1 correlates with Liver, C2 with Heart, C3 with Spleen, C4 with Lung, and C5–C10 with Kidney and San Jiao. Within this framework, establishing whether the ratio (or absolute intensity) of C2 and C3 exhibits a quantifiable dose-response curve with syndrome severity is the critical evidence chain advancing TCM diagnosis from “empirical judgment” to “frequency fingerprinting.”
Core Evidence Review
1. Overall Application of Harmonic Analysis in TCM Diagnosis (Systematic Review)
A systematic review by Hsiao et al. published in J Tradit Complement Med (PMID 38481553; 50 reports from 1990–2021) confirmed: C1 changes correlate with liver dysfunction; C3 (spleen-related) attenuation occurs in diabetic patients; cancer patients exhibit harmonic features of liver-kidney Yin deficiency in C1 and C2; cardiovascular disease patients manifest elevated first harmonics related to the Liver meridian. The review explicitly states that “harmonic intensity patterns exhibit distinguishable characteristics under different physiological and pathological states,” yet simultaneously emphasizes that “small sample sizes and high study heterogeneity” remain the primary limitations—precisely the reason why the “dose-response relationship” of interest in this topic has not yet been independently verified within a rigorous statistical framework.
2. Harmonic Characteristics in Cardiovascular Disease Populations
Chang et al. (2016; Microvasc Res; PMID 27067750) conducted PPG harmonic analysis on patients with Metabolic Syndrome (MetS), showing significant reductions in C1 and C2, while C4–C9 showed significant or trend-wise increases; the standard deviation and coefficient of variation for $C_n$ were maximal in the MetS group. This study suggests a association between C1/C2 attenuation and cardiovascular dysfunction, but the cross-sectional, single-center design (n=65) precludes establishing a continuous curve correlating severity grading with harmonic ratios.
3. Feasibility of Five-Zang Harmonics–ML Classification
Wu et al. (2022; Sci Rep; PMID 36509825) utilized 40 harmonic indicators (amplitude ratios + coefficient of variation + phase + standard deviation) for Linear Discriminant Analysis (LDA) classification in sarcopenia, achieving an AUC of 0.77 (scoring system AUC=0.83). This demonstrates that combined multi-harmonic features can achieve acceptable discriminative power in moderate sample sizes—the key to this topic is not whether a single harmonic is useful, but how the specific C2/C3 harmonic ratio can quantify Heart Qi Deficiency grading.
4. Bidirectional Calibration Basis for Harmonics-Syndrome Mapping
Chen et al. (2020; Evid Based Complement Alternat Med; PMID 33082826) confirmed that “relaxation activities increase higher harmonics while stress activities increase lower harmonics,” suggesting physiological state changes reflect through C1–C10 proportional relationships; Wu et al. (2016; PLoS One; PMID 27304979) provided methodological foundations via Synchrosqueezing Transform for fine-frequency domain analysis of Heart Qi Deficiency grading; Lin et al. (2021; Sci Rep; PMID 33903610) applied 40 harmonic indicators for Alzheimer’s disease classification with AUC≈0.85, further supporting the transferability of the “multi-harmonic combination + ML” paradigm across different zang-fu systems.
Key Gaps in Current Research
Synthesizing the above evidence reveals three specific evidence gaps for Project #88 (Heart Qi Deficiency mild/moderate/severe three-level dose-response):
- Missing Dose-Response Curve for “Single Syndrome-Single Harmonic Pair”: Existing studies are predominantly binary (disease/control) or ternary (healthy/pre-clinical/disease), lacking continuous modeling of “mild-moderate-severe” grading within a single syndrome pattern in TCM diagnosis.
- Lack of Confounding Correction for C2/C3 Ratio: Heart Qi Deficiency often coexists with Qi-Yin Deficiency or Heart-Spleen Deficiency; both C2 and C3 are simultaneously influenced by multiple organ functions. Existing studies fail to control for comorbid syndromes, contaminating the dose-response relationship with combined effects.
- Methodological Heterogeneity Prevents Meta-Analysis: The review (PMID 38481553) already declares “measurement methods and population heterogeneity” as primary defects; differences in acquisition devices (PPG/pressure sensors), varying palpation pressures, and disparate sample sizes limit cross-study comparability of harmonic ratios.
Hypotheses and Dose-Response Expectations
Based on harmonic theory and existing evidence, the working hypothesis for this project is:
Controlling for age, gender, BMI, comorbid syndromes, and acquisition pressure, the C2 (Heart-related) / C3 (Spleen-related) ratio will monotonically decrease with increasing severity of Heart Qi Deficiency (mild → moderate → severe), with the slope reflecting the degree of “functional reserve” consumption in Heart Qi.
The rationale for this hypothesis is: as Heart Qi Deficiency worsens, cardiac pumping function declines → absolute intensity of the C2 component in the radial artery wave decreases; concurrent Spleen Deficiency simultaneously lowers C3. If C2/C3 decrease synchronously, the ratio change serves as a differentiation indicator between “Heart Qi Deficiency dominant” vs. “Heart-Spleen Deficiency”; if C2 decreases while C3 remains unchanged (i.e., C2/C3 decreases), the ratio becomes a specific dose-response marker for Heart Qi Deficiency.
Evidence Boundaries and Limitations
- Existing PMID evidence consists of cross-sectional or retrospective studies, unable to support causal inference;
- Diagnostic criteria for Heart Qi Deficiency vary across different TCM diagnostic standards (1993 / 2017 / 2023), leading to label drift within the same population—this project must explicitly anchor which standard version in experimental design;
- Harmonic-syndrome mapping currently relies on the “Meridian-Zang-Fu-Harmonic” hypothesis (E2 indirect evidence chain), not yet proven as causality;
- The C2/C3 ratio is sensitive to acquisition pressure and must be paired with PCHR pressure compensation (referenced in Pool #32 project) to ensure cross-study comparability.
Proposed Next Steps
This project recommends executing a “three-stage, single-center prospective + multi-center external validation” study (see accompanying experimental design P3-EXP-023):
- Stage One: N=60 healthy controls vs. N=180 Heart Qi Deficiency (60 mild, 60 moderate, 60 severe) single-center; collect PPG + radial artery pressure waves;
- Stage Two: N=300 large-sample validation of the dose-response curve, incorporating confounding adjustments (age/gender/BMI/comorbid syndromes);
- Stage Three: N=120 multi-center external validation + cross-device transferability testing with PCHR pressure compensation.
Expected outputs: Three-segment reference intervals for C2/C3 ratio (mild/moderate/severe) + trend p-values after confounding adjustment + cross-device ICC.
Evidence Level Description
- Level A: RCT or multi-center prospective cohort directly proving (currently missing)
- Level B: Multi-study indirect evidence chain + systematic review support (current position of this project)
- Level C: Single-center cross-sectional or retrospective studies (most existing PMIDs fall into this layer)
Prior to obtaining Stage Two and Stage Three evidence, this project should maintain Level B (indirect evidence chain); upon completion of Stage Two, it may ascend to A- (single-center prospective); completion of Stage Three may challenge Level A.
Related Reading
- Pool #87: Evidence mapping on discriminative ability of pulse harmonic spectrum vs. time-domain features for syndrome differentiation
- Pool #32: Deep learning adaptive pressure compensation algorithm for PCHR (Experiment ID P3-EXP-016)
- Pool #29: Pressure normalization algorithm and cross-operator HRI comparability validation (PMID 27861248, 27314975, 31730401, 33901427, 1402.6649)
- Pool #23: Standardization of operator training for inter-operator reliability of 28-pulse HRI
Disclaimer
This article serves as a research review and project framework, does not constitute medical advice. Heart Qi Deficiency diagnosis and treatment must be conducted by licensed TCM practitioners; HRI harmonic analysis is a research tool, and clinical diagnosis requires comprehensive judgment combining symptoms, tongue/pulse examination, and laboratory tests.
Leave a Reply